

- 2014, Vol. 12, No.1, pp. 60-68, doi: 10.1089/bio.2013.0064
- [28] Gee S. et al, Biobank Finances: A Socio-Economic Analysis and Review, *Biopreservation and Biobanking*, Vol.13, No.6, 2015, doi: 10.1089/bio.2015.0030
- [29] Malsagova K. et al, Biobanks: A Platform for Scientific and Biomedical Research, *Diagnostics*, Vol.10, No.7, 2020, doi:10.3390/diagnostics10070485(2020).
- [30] Rush A, et al, Improving Academic Biobank Value and Sustainability Through an Outputs Focus, *Value in Health*, Vol.23, No.10, 2020, doi: 10.1016/j.jval.2020.05.010.
- [31] Ciaburri M. et al, Business Planning in Biobanking: How to implement a tool for sustainability, *Biopreservation and Biobanking*, Vol.15, No.1, pp. 46-56, 2017, doi:10.1089/bio.2016.0045
- [32] Chalmers D. et al, Has the biobank bubble burst? Withstanding the challenges for sustainable biobanking in the digital era, *BMC Medical Ethics*, 2016, pp. 17:39.
- [33] Bemmels H.R., Wolf S.M. and Ness B.V., Mapping the inputs, analyses, and outputs of biobank research systems to identify sources of incidental findings and individual research results for potential return to participants, *Genetics in Medicine*, Vol.14, pp. 385-392, 2012, doi:10.1038/gim.2011.69
- [34] Zika E. et al., *Biobanks in Europe: Prospects for Harmonisation and Networking*, JRC Working Papers JRC57831, Seville: Joint Research Centre; 2010.
- [35] Yuille M., Brave New World. Commentary, *Biopreservation and Biobanking*, Vol.13, No. 6, 2015, doi:10.1089/bio.2015.29040.my
- [36] Asslauer M, Zatloukal K, Biobanks: transnational, European and global networks, *Brief Funct Genomic Proteomic*, Vol. 6, No. 3, 2007, pp. 193-201.
- [37] Schulte In Den Baumen T, Paci D and Ibarreta Ruiz D., Data Protection and Sample Management in Biobanking - A legal dichotomy, *Genomics, Society and Policy*, Vol. 6, No. 1, pp. 34-47, 2010
- [38] BBMRI-ERIC. Directory. <https://www.bbMRI-eric.eu/directory/> Accessed 20.10.2021
- [39] Simeon-Dubach D., Henderson M. K., Sustainability in Biobanking, *Biopreservation and Biobanking*, Vol. 12, No.5, 2014, doi: 10.1089/bio.2014.1251
- [40] Barnes R.O, Watson P.H, Precision medicine: Driving the evolution of biobanking quality, *Healthc Manage Forum*, Vol. 33, No.3, 2020, <https://doi.org/10.1177/0840470419898874>
- [41] Hofman V. et. al, Measuring the contribution of tumor biobanks to research in oncology: surrogate indicators and bibliographic output, *Biopreservation and Biobanking*, Vol. 11, No.4, 2013, doi: 10.1089/bio.2013.0015.
- [42] Wu D. et al, Ten Years of the Cohort Biobank: Bibliometric Outcomes, *Biopreservation and Biobanking*, Vol. 19, No.4, 2021, doi: 10.1089/bio.2020.0096.
- [43] Hartman V, Matzke L, Watson P.H, Biospecimen Complexity and the Evolution of Biobanks, *Biopreservation and Biobanking*, Vol.17, No.3, 2019, doi: 10.1089/bio.2018.0120
- [44] Hughes S.E, Barnes R.O, Watson P.H, Biospecimen Use in Cancer Research Over Two Decades, *Biopreservation and Biobanking*, Vol. 8, No. 2, 2010, doi: [10.1089/bio.2010.0005](https://doi.org/10.1089/bio.2010.0005)
- [45] Henderson G.E, et al, Characterizing biobank organizations in the US: results from a national survey, *Genome Medicine*, Vol. 5, No.1, 2013, doi: 10.1186/gm407
- [46] Henderson M.K, Goldring K, Simeon-Dubach D, Advancing Professionalization of Biobank Business Operations: A Worldwide Survey, *Biopreserv Biobank*, Vol.17, No.1, 2020, doi: 10.1089/bio.2018.0079.
- [47] Doucet M. et al, Biobank sustainability: current status and future prospects, *Journal of Biorepository Science for Applied Medicine*, Vol. 5, pp.1-7, 2017, doi: [10.2147/BSAM.S100899](https://doi.org/10.2147/BSAM.S100899)
- [48] Boyer G.J. et al., Biobanks in the United States: How to Identify an Undefined and Rapidly Evolving Population, *Biopreservation and Biobanking*, Vol.10, No.6, 2012, doi:10.1089/bio.2012.0034
- [49] Kinkorová J, Topolčan O, Biobanks in Horizon 2020: sustainability and attractive perspectives, *EPMA J*, Vol. 9, No. 4, 2018, doi 10.1007/s13167-018-0153-7
- [50] Meijer I. et al, *BBMRI: an evaluation strategy for socio-economic impact assessment*. Technopolis Group, 2010, http://www.technopolis-group.com/resources/downloads/life_sciences/1093_BBMRIfi... Accessed 17.5.2021
- [51] UK biobank. Our impact. <https://www.ukbiobank.ac.uk/learn-more-about-uk-biobank/our-impact> Accessed 18.10.2021

- [52] ISBER. Anual report 2020.
https://cdn.ymaws.com/www.isber.org/resource/resmgr/isber_2020/annualreport/isberannualreport2020_final.pdf Accessed 18.10.2021
- [53] BBMRI-ERIC. <https://www.bbmri-eric.eu/national-nodes/> Accessed 18.10.2021
- [54] Sudoi A., De Vries J. and Kamuya D, A scoping review of considerations and practices for benefit sharing in biobanking, *BMC Medical Ethics*, 2021, Vol. 22, No. 102
- [55] Rogers J. et al, Biobankonomics: A Taxonomy for evaluating the economic benefits of standardized centralized human biobanking for translational research, *Journal of the National Cancer Institute Monographs*, Vol. 42, 2011, pp. 32-38
- [56] Caenazzo L, Tozzo P, The Future of Biobanking: What is next?, *BioTech*, Vol. 9, No. 4, 2020, doi: 10.3390/biotech9040023

Contribution of individual authors to the creation of a scientific article (ghostwriting policy)

Conceptualization - Ľubica Kotorová Slušná, Miroslav Balog
Methodology - Vladimír Baláž, Martina Antošová, Ľubica Kotorová Slušná
Writing — original draft preparation - Ľubica Kotorová Slušná, Vladimír Baláž, Miroslav Balog and Richard Filčák
Writing — review and editing – Edita Nemcová, Tomáš Jeck, Martina Antošová
Supervision - Vladimír Baláž, Miroslav Balog
Funding acquisition - Miroslav Balog, Martina Antošová

Sources of funding for research presented in a scientific article or scientific article itself

This publication has been produced with the support of the Integrated Infrastructure Operational Program for the project: Systemic public research infrastructure - biobank for cancer and rare diseases, ITMS: 313011AFG5, co-financed by the European Regional Development Fund

Creative Commons Attribution License 4.0 (Attribution 4.0 International , CC BY 4.0)

This article is published under the terms of the Creative Commons Attribution License 4.0
https://creativecommons.org/licenses/by/4.0/deed.en_US

Appendix

Figure 4 Correlation between total population and the total number of projects (Participant country in blue, Coordinator country in red)





Fig. 7 Regional or global biobanking organisations, initiatives or projects according to the date of their creation



Notes: International Society for Biological and Environmental Repositories (ISBER), Australian Biospecimen Network Association (ABNA), Canadian Tissue Repository Network (CTRnet), The European Clinical Research Infrastructure Network (ECRIN), Public Population Project in Genomics and Society (P3G), European Association for Predictive, Preventative and Personalized Medicine (EPMA), Global Alliance for Genomics and Health (GA4GH), The European, Middle Eastern & African Society for Biopreservation & Biobanking (ESBB), National BioService (NBS), The Human Heredity and Health in Africa (H3 Africa), Bridging Biobanking and Biomedical Research across Europe and Africa (B3Africa), Low and middle income countries (LMIC) Biobank and cohort building network (BCNet)